The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
 
Masato Ozaka
Honoraria - AstraZeneca; Bayer; EA Pharma; Eisai; MSD; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Makoto Ueno
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Merck Serono; MSD; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma; AstraZeneca (Inst); Chugai Pharma; Delta-Fly Pharma; Eisai (Inst); Incyte (Inst); JPH Clinical Development; Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Hiroshi Ishii
Honoraria - Lilly Japan; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Ono Pharmaceutical
 
Junki Mizusawa
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Hiroshi Katayama
No Relationships to Disclose
 
Tomoko Kataoka
No Relationships to Disclose
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Eisai; Nihon Servier; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Masafumi Ikeda
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; Micron; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Haruo Miwa
No Relationships to Disclose
 
Shuichi Kaneko
No Relationships to Disclose
 
Tomohiro Maesono
No Relationships to Disclose
 
Nobumasa Mizuno
Honoraria - MSD; Yakult Honsha
Consulting or Advisory Role - AstraZeneca
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
Travel, Accommodations, Expenses - Novartis
 
Tomohisa Yamamoto
No Relationships to Disclose
 
Yasuyuki Kawamoto
Honoraria - Lilly; Merck; Taiho Pharmaceutical
Research Funding - Japan Agency for Medical Research and Development
 
Akiko Todaka
Honoraria - Yakult Honsha
 
Ken Kamata
No Relationships to Disclose
 
Terumasa Hisano
No Relationships to Disclose
 
Nao Fujimori
No Relationships to Disclose
 
Junji Furuse
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Kyowa Hakko Kirin; Lilly Japan; Merck; Mochida Pharmaceutical Co. Ltd.; MSD; Mylan; Nihon Servier; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Shionogi; Shire; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Lilly Japan; Merck; MSD; Mundipharma; Novartis; OncoTherapy Science; Ono Pharmaceutical; Otsuka; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)